

K112387

ATTACHMENT 2  
510(K) SUMMARY

DEC 27 2011

PROcedure™ Rehearsal Studio

510(k) Number K\_\_\_\_\_

**Applicant's Name:**

Beit Golan  
Corner of Golan and Hanegev St.  
Airport City, 70151, Israel  
Tel: +972-3-9114444  
Fax: +972-3-9114455

**Contact Person:**

Shoshana (Shosh) Friedman  
Telephone: 704-899-0092  
Fax: 704-899-0098  
Email: shosh@pushmed.com

**Trade Name:**

PROcedure Rehearsal Studio™

Classification Name:	System, Image Processing, Radiological
Regulation Number:	892.2050
Product Code:	LLZ
Classification:	Class II
Review Panel:	Radiology

**Predicate Device:**

- PROcedure Rehearsal Studio™ cleared for marketing under K093269
- Mimics® by Materialise N.V. cleared for marketing under K073468.

**Device Description:**

The Simbionix PROcedure Rehearsal Studio software allows clinicians to create a patient specific 3D anatomical model based on a patient's CT for the purpose of simulating, analyzing and evaluating for preoperative surgical treatment options.

Once the 3D segmentation model has been exported to the Simbionix ANGIO Mentor Simulator Practice Environment, the physician can use it to create a library of modules for training and post-operative debriefing. The modifications subject to this Special 510(k) submission are: (1) Graphic User Interface changes in various locations; (2) functional change in various locations which include the addition of an EVAR module that allows the software to create 3D models of abdominal scans in addition to the carotid option that was previously cleared.

**Intended Use:**

The PROcedure Rehearsal Studio software is intended for use as a software interface and image segmentation system for the transfer of imaging information from a medical scanner such as a CT scanner to an output file. It is also intended as pre-operative software for simulating/evaluating surgical treatment options.

**Performance Data:**

The company has performed extensive verification and validation activities to ensure the device performs according to its specifications.

**Conclusion:**

Simbionix Ltd. believes that, based on the information provided in this submission, the modified PROcedure Rehearsal Studio™ is substantially equivalent to the predicate PROcedure Rehearsal Studio previously cleared for marketing under K093269 without raising any new safety and/or effectiveness issue.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room – WO66-G609  
Silver Spring, MD 20993-0002

Simbionix, Ltd.  
% Ms. Shoshana Friedman, RAC  
Regulatory Consultant  
Push-Med, LLC.  
1914 J. N. Pease Place  
CHARLOTTE NC 28262

DEC 27 2011

Re: K112387  
Trade/Device Name: PROcedure™ Rehearsal Studio  
Regulation Number: 21 CFR 892.2050  
Regulation Name: Picture archiving and communications system  
Regulatory Class: II  
Product Code: LLZ  
Dated: November 30, 2011  
Received: December 2, 2011

Dear Ms. Friedman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,

A handwritten signature in black ink, appearing to read "Mary S. Pastel". The signature is fluid and cursive, with a long horizontal stroke at the beginning.

Mary S. Pastel, Sc.D.  
Director  
Division of Radiological Devices  
Office of In Vitro Diagnostic Device  
Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

## ATTACHMENT 1

### INDICATIONS FOR USE STATEMENT

510(k) Number: \_\_\_\_\_

Device Name:

PROcedure™ Rehearsal Studio

Indications for Use:

The PROcedure Rehearsal Studio software is intended for use as a software interface and image segmentation system for the transfer of imaging information from a medical scanner such as a CT scanner to an output file. It is also intended as pre-operative software for simulating/evaluating surgical treatment options.

Prescription Use   X  

OR

Over the Counter Use \_\_\_\_\_

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)



(Division Sign-Off)

Division of Radiological Devices  
Office of In Vitro Diagnostic Device Evaluation and Safety

510K

K112387